Charles Bennett to Antineoplastic Agents
This is a "connection" page, showing publications Charles Bennett has written about Antineoplastic Agents.
Connection Strength
9.458
-
The First 2?Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist. 2021 08; 26(8):e1418-e1426.
Score: 0.429
-
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. PLoS One. 2020; 15(6):e0234541.
Score: 0.408
-
End of an era for erythropoiesis-stimulating agents in oncology. Int J Cancer. 2020 05 15; 146(10):2829-2835.
Score: 0.399
-
Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions. PLoS One. 2019; 14(7):e0219521.
Score: 0.383
-
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
Score: 0.373
-
Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA. Lancet Oncol. 2017 01; 18(1):22-23.
Score: 0.321
-
Generic oncology drugs: are they all safe? Lancet Oncol. 2016 Nov; 17(11):e493-e501.
Score: 0.317
-
Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia. Br J Haematol. 2018 01; 180(2):301-304.
Score: 0.315
-
Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system. Expert Opin Drug Saf. 2016 Aug; 15(8):1003-11.
Score: 0.309
-
Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry. Leuk Res. 2016 May; 44:61-4.
Score: 0.303
-
Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment. JAMA Oncol. 2016 Feb; 2(2):274-6.
Score: 0.301
-
Screening for viral hepatitis prior to rituximab chemotherapy. Ann Hematol. 2016 Jan; 95(1):27-33.
Score: 0.293
-
Japanese regulatory authority's perspective on biosimilars - authors' reply. Lancet Oncol. 2015 Mar; 16(3):e102.
Score: 0.282
-
Geography: an increasingly important variable in prostate cancer clinical trials. BJU Int. 2015 Jan; 115(1):2-3.
Score: 0.279
-
Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014 Dec; 15(13):e594-e605.
Score: 0.277
-
Toxicity and costs of toxicity associated with new cancer drugs: international implications. J Clin Oncol. 2014 Nov 10; 32(32):3591-2.
Score: 0.274
-
Reply to W. Read. J Clin Oncol. 2014 Feb 20; 32(6):604-5.
Score: 0.261
-
Finishing the picture: problems with public reporting of clinical trials. J Clin Oncol. 2013 Aug 20; 31(24):2981-2.
Score: 0.253
-
Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012 Nov; 38(8):759-67.
Score: 0.240
-
Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents. Arch Intern Med. 2010 Sep 13; 170(16):1490-8.
Score: 0.207
-
Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park). 2010 Mar; 24(3):260-8.
Score: 0.200
-
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008 Dec; 9(12):1166-72.
Score: 0.183
-
Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer. 2008 Sep 15; 113(6):1446-52.
Score: 0.180
-
Adverse effects of drugs used to treat hematologic malignancies: surveillance efforts from the research on adverse drug events and reports project. Semin Thromb Hemost. 2007 Jun; 33(4):365-72.
Score: 0.165
-
Reducing adverse drug events in the outpatient chemotherapy setting: attention must be paid. Cancer. 2005 Dec 01; 104(11):2289-91.
Score: 0.149
-
Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs. J Clin Oncol. 2005 Dec 01; 23(34):8894-905.
Score: 0.149
-
Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited. Pharmacoeconomics. 2005; 23(8):767-75.
Score: 0.140
-
A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians. Gynecol Oncol. 2004 Apr; 93(1):164-9.
Score: 0.132
-
Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol. 2003 Oct 15; 21(20):3859-66.
Score: 0.128
-
Cost-effectiveness considerations in the treatment of essential thrombocythemia. Semin Oncol. 2002 Jun; 29(3 Suppl 10):28-32.
Score: 0.117
-
Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias. J Clin Epidemiol. 2022 08; 148:193-195.
Score: 0.114
-
Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series. Br J Dermatol. 2022 01; 186(1):153-166.
Score: 0.112
-
Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest. 2001; 19(2):107-13.
Score: 0.106
-
Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors. Cancer Med. 2019 05; 8(5):2233-2240.
Score: 0.094
-
The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 1):40-5.
Score: 0.093
-
Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients. Cancer Invest. 1999; 17(8):559-65.
Score: 0.092
-
Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma. Acta Oncol. 1999; 38(8):1063-7.
Score: 0.092
-
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. J Oncol Pract. 2017 06; 13(6):e562-e573.
Score: 0.082
-
Interpretation of surrogate endpoints in the era of the 21st Century Cures Act. BMJ. 2016 Dec 30; 355:i6286.
Score: 0.080
-
Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. JAMA Oncol. 2016 Jan; 2(1):134-6.
Score: 0.075
-
Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin Cancer Res. 2011 Feb 01; 17(3):560-8.
Score: 0.053
-
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol. 2009 Sep 10; 27(26):4398-405.
Score: 0.048
-
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res. 2009 Jun 01; 15(11):3850-5.
Score: 0.047
-
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009 May 14; 113(20):4834-40.
Score: 0.047
-
Myeloid growth factors. J Natl Compr Canc Netw. 2009 Jan; 7(1):64-83.
Score: 0.046
-
Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer. Semin Dial. 2009 Jan-Feb; 22(1):1-4.
Score: 0.046
-
Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2008 Jul; 6(6):536-64.
Score: 0.044
-
Dermatologic challenges in cancer patients and survivors. Oncology (Williston Park). 2007 Nov; 21(12):1462-72; discussion 1473, 1476, 1481 passim.
Score: 0.042
-
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008 Jan 01; 26(1):132-49.
Score: 0.042
-
Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Feb; 5(2):188-202.
Score: 0.040
-
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007 May; 31(5):599-604.
Score: 0.039
-
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006 May 17; 98(10):708-14.
Score: 0.038
-
When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective? J Clin Oncol. 2006 Jul 01; 24(19):2975-7.
Score: 0.038
-
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med. 2004 Jan 01; 116(1):28-34.
Score: 0.033
-
Cost analyses of granulocyte colony stimulating factor: a focus on older patients with cancer. Crit Rev Oncol Hematol. 2003 Oct 15; 48(Suppl):S71-4.
Score: 0.032
-
Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. Med Pediatr Oncol. 2000 Feb; 34(2):92-6.
Score: 0.025
-
Pharmacoeconomics of amifostine in ovarian cancer. Semin Oncol. 1999 Apr; 26(2 Suppl 7):102-7.
Score: 0.023
-
Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists. Gynecol Oncol. 1998 Dec; 71(3):369-75.
Score: 0.023
-
Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials. Stem Cells. 1995 Jul; 13(4):414-20.
Score: 0.018
-
Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int. 2012 Jul; 110(2):201-5.
Score: 0.014
-
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008 Jan 01; 111(1):25-41.
Score: 0.011